Inicio | Personas | Núria Malats

Núria Malats

Dr. Malats was born in Barcelona and got her MD in 1986 (Universitat Autònoma de Barcelona). During her Ph.D., she carried out experimental and epidemiological work on the association of K-ras mutations with both environmental exposures and clinical outcomes of pancreas cancer. This work was carried out at Institut Municipal d’Investigació Mèdica (IMIM), Barcelona, under the supervision of Drs. Miquel Porta and Francisco X Real. She got her PhD in 1995 at Universitat Autònoma de Barcelona. She also coordinated a multicenter Spanish project on pancreas cancer (PANKRAS2) integrating multidisciplinary interests in environmental, clinical, and molecular epidemiology.

From 1996-1998 she was visiting scientist at the International Reseach on Cancer (IARC-WHO), Lyon, in the group of Dr. Paolo Boffeta, where she initiated her training in genetic epidemiology. She returned to IMIM in 1998 and obtained a research contract of the Sistema Nacional de Salud, ISCIII.


Since 1997, together with Dr. Real (CNIO), Dr. Kogevinas (IMIM, Barcelona), and Drs. Rothman, Silverman and Dosemeci from NCI-NIH, USA, she is a co-PI of the Spanish Bladder Cancer /EPICURO Study, a large case-control study on bladder cancer that integrates scientific interests from different disciplines in both cancer development and progression.

Before joining CNIO in September 2007, she was Scientist at Centre de Recerca en Epidemiologia Ambiental (CREAL-IMIM), leading and participating in both national and international competitive funded projects and coordinating the Spanish research network on bladder cancer (EPICUR-red).

Dr. Malats is the Spanish delegate of the Public Health and Genomics European Network (PHGEN). She has coordinated and participated in teaching activities in under and postgraduate courses at several Spanish Universities. She has over 100 publications and is external reviewer of national and international funding agencies and first rank scientific journals. She is also member of the Scientific Board of the European Society of Urological Research (ESUR), and the European Association of Urology Foundation Research. Her work at CNIO is focused on the genetic and molecular epidemiology of cancer.

Subir